| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Health Policy & Services |
| Manuscript Type |
Opinion Review |
| Article Title |
Why does hepatitis B remain underprioritized? A view through lived experience
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yasmin Ibrahim, Anousha Qureshi, Michaela Jackson, Beatrice Zovich, Catherine Freeland, Monue Flomo, Kenson Alik, Ravshan Yakubov, Li Hui Chen, Philip Kwame Yeboah and Chari Cohen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yasmin Ibrahim, Associate Professor, Director, MD, Principal Investigator, Senior Researcher, Patient Engagement Program, Hepatitia B Foundation, Yasmin Ibrahim, Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, Pennsylvania, United States, 18902-8400.
Email: <email>yasmin.ibrahim@hepb.org</email>, Doylestown, Pennsylvania, 18902, United States. yasmin.ibrahim@hepb.org |
| Key Words |
Hepatitis B; Elimination; Under-prioritization; Health equity; Global; Hepatitis B virus; Chronic hepatitis B; People living with hepatitis B virus |
| Core Tip |
The article explores why chronic hepatitis B (CHB) infection, despite affecting 260 million people globally, remains underprioritized. Only 3% of those infected receive treatment, and stigma, discrimination, and systemic neglect persist. Through lived experiences of people with hepatitis B worldwide, this article explores barriers to progress-such as marginalization of impacted population and inequitable funding among others, and draws lessons from human immunodeficiency virus, coronavirus disease 2019, and Ebola, where advocacy, political will, and investment drove change. It calls for stronger collaboration, greater investment in care and prevention, integration of disease programs, and inclusion of patient-reported outcomes to accelerate elimination and improve the lives of people living with hepatitis B. |
| Publish Date |
2026-04-23 11:05 |
| Citation |
Ibrahim Y, Qureshi A, Jackson M, Zovich B, Freeland C, Flomo M, Alik K, Yakubov R, Chen LH, Yeboah PK, Cohen C. Why does hepatitis B remain underprioritized? A view through lived experience. World J Methodol 2026; 16(2): 114604 |
| URL |
https://www.wjgnet.com/2222-0682/full/v16/i2/114604.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v16.i2.114604 |
